Generate Biomedicines (GENB) news
Recent news
Biomedicines and Zealand Pharma enter collaboration and license agreement to develop protein therapeutics engineered with AI for metabolic diseases
AInvest Wire · 7h agoZeland Pharma makes deal with Generate worth up to $1.2 billion - Bloomberg News
AInvest Wire · 7h agoBiomedicines - GB-5267 targets MUC16 biomarker in over 80% of ovarian tumors
On October 1, 2026, Generate Biomedicines (NASDAQ: GBIO) announced the development of GB-5267, a novel therapeutic candidate targeting the MUC16 biomarker, which is present in over 80% of ovarian tumors. This advancement aligns with the company’s broader strategy to leverage artificial intelligence…
AInvest Wire · Oct 1, 2026Generate Biomedicines: Existing cash, cash equivalents, and marketable securities sufficient to fund current operating plan into H1 2028
Generate Biomedicines, Inc. (NASDAQ: GENB) reported that as of March 31, 2026, it held $516.6 million in cash , cash equivalents, and marketable securities. The company stated that these funds are expected to be sufficient to support its current operating plan through the first half of 2028. This…
AInvest Wire · Aug 6, 2026Generate Biomedicines - Q2 revenue $6.30 mln
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.